Caricamento...

Gefitinib enhances sensitivity of endometrial cancer cells to progestin therapy via dual-specificity phosphatase 1

In this study, we investigated if Gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, augments endometrial cancer (EC) therapy with medroxyprogesterone acetate (MPA). Combined treatment with Gefitinib plus MPA decreased the proliferation and invasiveness of the Ishikawa and RL952 EC cel...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Yang, Yuan, Zhou, Jingyi, Li, Xiaoping, Zhao, Lijun, Cheng, Yuan, Lin, Yanying, Wang, Jiaqi, Wei, Lihui, Dong, Yafeng, Wang, Jianliu
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2017
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5777777/
https://ncbi.nlm.nih.gov/pubmed/29383165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23264
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !